Bernstein Sticks to Their Hold Rating for BioNTech SE (BNTX)
TipRanks (Tue, 2-Jun 9:01 AM ET)
TipRanks (Mon, 1-Jun 8:33 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Mon, 1-Jun 8:10 AM ET)
TipRanks (Mon, 1-Jun 7:31 AM ET)
Globe Newswire (Sat, 30-May 2:15 PM ET)
Lamb Weston, FedEx, BioNTech, Zscaler, Larimar Trending With Analysts
TipRanks (Sat, 30-May 5:01 AM ET)
EU to target XFG variant for next COVID vaccines
Seeking Alpha News (Fri, 29-May 12:10 PM ET)
FDA panel backs XFG strain for 2026-27 COVID vaccine update
Seeking Alpha News (Fri, 29-May 5:00 AM ET)
Canaccord Genuity Sticks to Its Buy Rating for BioNTech SE (BNTX)
TipRanks (Thu, 28-May 7:43 AM ET)
BioNTech to Highlight Late-Stage Oncology Pipeline with 25+ Active Trials at ASCO 2026
Market Chameleon (Fri, 22-May 3:07 AM ET)
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Biontech Se - American Depositary Shares trades on the NASDAQ stock market under the symbol BNTX.
As of June 2, 2026, BNTX stock price declined to $89.14 with 910,399 million shares trading.
BNTX has a beta of 1.59, meaning it tends to be more sensitive to market movements. BNTX has a correlation of 0.21 to the broad based SPY ETF.
BNTX has a market cap of $22.54 billion. This is considered a Large Cap stock.
Last quarter Biontech Se - American Depositary Shares reported $138 million in Revenue and -$2.28 earnings per share. This fell short of revenue expectation by $-77 million and exceeded earnings estimates by $.24.
In the last 3 years, BNTX traded as high as $131.49 and as low as $76.53.
The top ETF exchange traded funds that BNTX belongs to (by Net Assets): FBT, IBB, TCAF, FNDF, ARKG.
BNTX has underperformed the market in the last year with a price return of -7.0% while the SPY ETF gained +30.1%. BNTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.1% and +0.3%, respectively, while the SPY returned +11.0% and +2.8%, respectively.
BNTX support price is $89.33 and resistance is $94.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNTX shares will trade within this expected range on the day.